Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502053-34-00

Acronym

GO39775

Enrollment

Registered

2024-02-27

Start date

2020-07-13

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma (MM)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026